Work

Supplementary Figure S3 from Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure S3 describes the effects of distinct MEK inhibitors in combination with BCL-2/XL inhibition and contribution of BCL-2 vs. BCL-XL to apoptotic vulnerability of HGSOC PDX models

DOI: 10.1158/1535-7163.22505631

Authors: Claudia Iavarone, Ioannis K. Zervantonakis, Laura M. Selfors, Sangeetha Palakurthi, Joyce F. Liu, Ronny Drapkin, Ursula A. Matulonis, Dorothy Hallberg, Victor E. Velculescu, Joel D. Leverson, Deepak Sampath, Gordon B. Mills, Joan S. Brugge

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362609972

Cites:

Cited by:

Related to: 10